- Home
- TLPH vs NTRB Comparison
TLPH vs NTRB Comparison
Compare TLPH & NTRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TLPH | NTRB |
|---|---|---|
| Founded | 2005 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Specialties |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 70.3M | 72.6M |
| IPO Year | 2010 | 2019 |
Fundamental Metrics
Financial Performance| Metric | TLPH | NTRB |
|---|---|---|
| Price | $1.18 | $8.00 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 102.2K | 98.2K |
| Earning Date | 05-13-2026 | 05-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,151,000.00 | $2,036,651.00 |
| Revenue This Year | N/A | $30.17 |
| Revenue Next Year | N/A | $3,394.36 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.69 | $2.80 |
| 52 Week High | $1.57 | $9.00 |
Technical Indicators
Market Signals| Indicator | TLPH | NTRB |
|---|---|---|
| Relative Strength Index (RSI) | 44.75 | 65.16 |
| Support Level | $1.17 | $3.68 |
| Resistance Level | $1.29 | N/A |
| Average True Range (ATR) | 0.04 | 0.97 |
| MACD | -0.00 | 0.08 |
| Stochastic Oscillator | 27.27 | 69.53 |
Price Performance
Historical ComparisonAbout TLPH Talphera Inc.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.
About NTRB Nutriband Inc.
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. Company operates in two reportable segments namely, Sales of Goods and Services. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.